您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > PI-3065
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PI-3065
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PI-3065图片
CAS NO:955977-50-1
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件

Molecular Weight (MW)

506.64

Formula

C27H31FN6OS

CAS No.

955977-50-1

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 50 mg/mL warming (98.7 mM)

Water:<1 mg/mL

Ethanol: <1 mg/mL

Synonym

PI-3065; PI3065; PI 3065.

Chemical Name

4-(6-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-2-(5-fluoro-1H-indol-4-yl)thieno[3,2-d]pyrimidin-4-yl)morpholine

实验参考方法

In Vitro

Kinase Assay: PI-3065 is a novel, potent and selective inhibitor of PI3K (phosphatidylinositol 3-kinase) p110δ inhibitor with potential anticancer activity. It inhibits p110δ with an IC50 of 15 nM, and showed>70-fold selectivity over other PI3K family proteins such as p110α, p110β, p110γ with IC50s of 910, 600,>10000 nM, respectively.


Cell Assay: Proliferation of 4T1 cells is assayed following a 4-h treatment with the indicated p110δ inhibitors, then washing and MTS staining are carried out after 48 h culture. PI-3065 shows no inhibition on the growth of 4T1 cells, which do not expressing detectable levels of p110δ

In Vivo

In mouse model, PI-3065 (75 mg/kg, p.o.) also suppresses 4T1 tumor growth and metastasis via inactivation of p110δ. In the LSL.KrasG12D/+; p53R172H/+; PdxCretg/+ (or KPC) model of pancreatic ductal adenocarcinoma, PI-3065 prolongs survival and reduces the incidence of macroscopic metastases and other disease-associated pathologies.

Animal model

Female WT BALB/c mice bearing 4T1 tumors

Formulation & Dosage

Dissolved in 0.5% methylcellulose with 0.2% Tween 80; 75 mg/kg; Oral administration

References

[1] Ali K, et al. Nature. 2014, 510(7505), 407-411.

生物活性


Impact of pharmacological inactivation of p110δ on tumour growth and T cell responses. Nature. 2014, 510(7505), 407-411.


Characterisation of the p110δ-selective inhibitor PI-3065